The biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants.
Support and Resistance...
LLY shown on a daily chart has doubled in the past year with the introduction of new FDA
approved drugs into the market. It has but out a series of favorable earnings reports with
optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume
pumps and just keeps grinding higher. This is because it is in the shadows of big...
LLY has given us Bearish RSI Confirmation at the 3.618 Fibonacci Extension and now looks to push below the $580 level. This could quickly devolve into LLY making a much deeper Bearish Retrace that would bring it below trend. At that point, we could very well see LLY come all the way back down to fill the gap at $163.42
If we close the day as we are now, we will have confirmed a 3 Line Strike, a Bearish PPO Arrow, and a break below the 5 EMA on the Daily Timeframe just above the 3.618 Fibonacci Extension. From there I would expect LLY to first Fill the gap at $451.50 and beyond that I think it will revisit the 200-day SMA around $350 and maybe even the 800-day EMA at around $285.
My analysis is on the 2H. I am uniquely qualified in my fundamental analysis. This is a one
day until earnings. My thesis is the earnings will stimulate what will be a breakout from
a flat bottom triangle. I will buy one share of stock. I will spend a similar amount on
call options striking $460 expiring August 11th. I see LLY as surging while PFE is a bit...
This strategy dissects the dual nature of big pharmaceutical firms like Johnson & Johnson, Pfizer, Moderna, and Merck & Co viewed through base Fibonacci Extension Clustering. Despite big pharma's significant contributions to healthcare, these firms have benefited from questionable practices, including price manipulation and exploiting addictions . Price...
On the 4H Chart LABU is trending up since March 27th. Last week there was a small pullback which was met with more buying activity.
On the volume indicator, the volume now is approximately 10X day by day compared with March's averages. It is this buying that is driving
the bullish momentum. Small-cap speculative biotech companies are in a growth mode right...
PFE just raised its dividend On the chart it has been trending downward
as shown also by a down sloping anchored VWAP bands. Price is currently
sitting at long term support and two standard deviations below VWAP.
It appears to be ready to reverse from the deep undervalued area.
In confirmation, teh voume indicator shows moderate increased...
NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality.
52 Week Range 2.38 - 48.80.
in 2020 the stock was $77.
My price target is 16.50
If this is not the time to buy this stock, then when?!
Havin a look is all. Such a move in PFE, worth reflecting on what Big Pharma really is. Do you know why USA is only country that allows TV commercials of Big Pharma? Any other countries? Why so many connections to FDA? Why so many connections to the Israelis and regular attendees at Bilderberg. People will dismiss these connections as tinfoil then drool over...
Moving average convergence/divergence crossover on multiple timeframes, RSI rising quickly out of overbought area, price bounced off of a long term price support/resistance line.
Target $70 : Tight stop loss
First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into my insights. There was rumors that AstraZeneca wanted to merge w/ Gilead. However, it looks like this may not happen. Until, the books are closed don't get your hopes up, but invest as if you expect...
EDIT and CRSP
CRISPR-Cas9, -Cas11, -Cas12 genetic improvements for bio-pharma partnerships
The next big thing to improving and repairing defects in you RNA
Currently at Fibretracement 0.618 and in spot to move up or down, depending on big money theory...wahahah!
but there's enough small money to pull it down, just saying for disclosure.
Consistent outperformer with always an Ace up its sleeve. Expect at least a 30% increase in value in 2016. You will never see this stock at these prices ever again. Buy now and thank me Later. All bets are off if we have a financial collapse dragging the share price below 92.96.
